IP Library Patent Application 16588331
Patent Application
App. No. 16/588,331

ANTIBODIES TO INTEGRIN AVB6 AND USE OF SAME TO TREAT CANCER

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/588,331
Abstract

The invention provides antibodies that specifically bind to integrin αvβ6. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting αvβ6.

Claims (19)

1 . A humanized antibody that specifically binds to the human integrin αvβ6 wherein the antibody comprises a mature heavy chain region having a heavy chain variable region having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO: 11 or 22, and a light chain variable region having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO: 25.

2 . The antibody of claim 1 , comprising a mature heavy chain region having a heavy chain variable region having the amino acid sequence set forth in SEQ ID NO: 11 or 22, and a mature light chain variable region having the amino acid sequence set forth in SEQ ID NO: 25.

3 . The antibody of claim 1 wherein the mature heavy chain variable region is fused to a heavy chain constant region and the mature light chain variable region is fused to a light chain constant region.

4 . The antibody of claim 3 , wherein the heavy chain constant region is a mutant form of a natural human constant region which has reduced binding to an Fc gamma receptor relative to the natural human constant region.

5 . The antibody of claim 3 , wherein the heavy chain constant region is of IgG1 isotype.

6 . The antibody of claim 1 , wherein the antibody is conjugated to a cytotoxic or cytostatic agent.

7 . The antibody of claim 6 , wherein the cytotoxic agent is vcMMAE or mcMMAF.

8 . A method of treating a patient having pancreatic cancer or head and neck cancer, comprising administering to the patient an effective regime of an antibody of claim 1 .

9 . A pharmaceutical composition comprising an antibody of claim 1 .

10 . An isolated polynucleotide comprising a sequence encoding a heavy chain variable region and a light chain variable region as defined in claim 1 .

11 . An isolated vector comprising the polynucleotide of claim 10 .

12 . An isolated host cell comprising the vector of claim 11 .

13 . A method of making an anti-αvβ6 antibody or antigen binding fragment thereof, wherein the method comprises:

a) culturing the host cell of claim 12 under conditions suitable for expression of the polynucleotide encoding the antibody or antigen binding fragment thereof; and

b) isolating the antibody or antigen binding fragment thereof.

14 . A method of making an anti-αvβ6 antibody drug conjugate, wherein the method comprises:

a) culturing the host cell of claim 12 under conditions suitable for expression of the polynucleotide encoding the antibody or antigen binding fragment thereof;

b) isolating the antibody or antigen binding fragment thereof; and

c) conjugating a cytotoxic agent to the antibody or antigen binding fragment thereof.

Assignments (1)
CHANGE OF NAME Recorded Oct 21, 2020
From: SEATTLE GENETICS, INC.
To: SEAGEN INC.
Reel/Frame 054174/0595 →